复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

交易中 04-30 14:38:28

74.500

-1.700

-2.23%

最高79.800	最低73.850	成交量44.10万
今开76.250	昨收76.200	日振幅7.81%
总市值404.54亿	流通市值257.83亿	总股本5.43亿
成交额3,312万	换手率0.13%	流通股本3.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":74.5,"timestamp":1777531056105,"preClose":76.2,"halted":0,"volume":441042,"delay":0,"changeRate":-0.022309711286089277,"floatShares":346074397,"shares":543000000,"eps":1.509618,"marketStatus":"交易中","change":-1.7,"latestTime":"04-30 14:38:28","open":76.25,"high":79.8,"low":73.85,"amount":33118336,"amplitude":0.078084,"askPrice":74.55,"askSize":1400,"bidPrice":74.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":1.680343,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777536600000},"marketStatusCode":2,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":76.2,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.798154,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"1198057523","title":"欧盟委员会批准复宏汉霖与Organon的Poherdy®（帕妥珠单抗） 成为欧洲首个获准的Perjeta（帕妥珠单抗）生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1198057523","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198057523?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:31","pubTimestamp":1777455074,"startTime":"0","endTime":"0","summary":"欧盟委员会正式批准了复宏汉霖与Organon公司联合开发的Poherdy®（帕妥珠单抗），该药物成为欧洲地区首个获得上市许可的Perjeta（帕妥珠单抗）生物类似药。这一批准标志着两家公司在生物制药领域取得重要突破，将为欧洲市场提供更多治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","BK4007","LU2065170008.USD","LU2065171311.SGD","HK0000320223.HKD","LU2065169927.USD","OGN","HK0000306685.HKD","BK1161","02696","HK0000320264.USD","HK0000165453.HKD","BK4585","BK4588","LU2065171402.SGD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630309173","title":"复宏汉霖(02696)自主研发的POHERDY®于欧盟获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2630309173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630309173?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:50","pubTimestamp":1777377048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主研发的POHERDY 420mg/14mL注射液的上市许可申请 已获欧盟委员会批准，该商品名由N.V. Organon于欧盟注册商标。此次获批意味着POHERDY 在所有欧盟成员国及冰岛、列支敦士登和挪威获得集中上市许可。继于美国获批上市之后，此次POHERDY于欧盟获批上市，是集团产品在国际主流市场获得的又一认可，将进一步推进公司国际化布局的进程，提升公司产品的国际影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","HK0000320264.USD","BK1161","HK0000306685.HKD","FESXmain","HK0000165453.HKD","HK0000306701.USD","02696","HK0000320223.HKD","FSXEmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128740396","title":"复宏汉霖旗下汉曲优®获欧盟批准用于治疗HER2阳性早期及转移性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740396","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128740396?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:49","pubTimestamp":1777376981,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司近日宣布，其核心产品汉曲优®（通用名：曲妥珠单抗）已获得欧盟委员会批准，用于治疗HER2阳性早期乳腺癌及转移性乳腺癌。此项批准标志着公司创新研发成果获得国际主流市场认可，为欧洲患者提供了重要的治疗选择。\nHER2阳性乳腺癌是一种侵袭性较强的乳腺癌亚型，汉曲优®作为曲妥珠单抗的生物类似药，在疗效与安全性方面与原研药高度相似。此次获批将进一步提升复宏汉霖在全球生物药市场的竞争力，并为其国际化战略注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000165453.HKD","HK0000306701.USD","BK1161","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189910896","title":"复宏汉霖Hlx07联合汉斯状®治疗晚期鳞状非小细胞肺癌II/III期临床试验获准在澳大利亚启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1189910896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189910896?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:16","pubTimestamp":1777025795,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其创新药Hlx07联合汉斯状®（HLX10）用于治疗晚期鳞状非小细胞肺癌的II/III期临床试验，已获得澳大利亚监管机构批准正式启动。\n该临床试验旨在评估Hlx07这一靶向EGFR的人源化单克隆抗体，与公司自主研发的PD-1抑制剂汉斯状®联合疗法的有效性与安全性。研究将聚焦于晚期鳞状非小细胞肺癌患者群体，这是肺癌中一种常见的亚型。\n此次在澳大利亚获批开展临床试验，标志着复宏汉霖的这款联合疗法研发项目取得了重要进展，为其全球临床开发布局再添关键一环。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306701.USD","HK0000165453.HKD","HK0000306685.HKD","BK1161","HK0000320223.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629817454","title":"复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗对比安慰剂联合汉斯状® 或帕博利珠单抗和化疗一线治疗晚期鳞状 非小细胞肺癌的2/3期临床试验于澳大利亚获批开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629817454","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629817454?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:15","pubTimestamp":1777025731,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的pimurutamab HLX07联合汉斯状(汉斯状)和化疗对比安慰剂联合汉斯状或帕博利珠单抗和化疗一线治疗晚期鳞状非小细胞肺癌的2/3期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。2026年3月，HLX07联合汉斯状和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗对比安慰剂联合汉斯状® 或帕博利珠单抗和化疗一线治疗晚期鳞状 非小细胞肺癌的2/3期临床试验于澳大利亚获批开展","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198094205","title":"复宏汉霖授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1198094205","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198094205?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:48","pubTimestamp":1777024097,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696)日前公告，拟向董事会授予一般性授权，以回购不超过股东大会通过决议当日已发行H股总数10%的股份。公司在香港联交所主板上市，回购计划将以合法资金来源进行，并根据上市规则和中国相关法律条款完成。\n公告显示，股东大会将于2026年5月19日召开，相关决议如获通过，公司有权在适用条例允许的期间内，于公开市场回购部分已发行H股。董事会认为，该购回有助于维护公司价值与股东利益，相关股份可在回购后根据实际情况进行注销或持作库存股。公司同期提示，2026年5月14日至5月19日将暂停办理过户登记，并以此期间登记在册的股东身份为准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158186060","title":"复宏汉霖2025年营收增长16.5%至66.67亿元，聚焦创新研发与全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1158186060","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158186060?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:42","pubTimestamp":1777023751,"startTime":"0","endTime":"0","summary":"复宏汉霖在截至2025年12月31日止年度实现收入人民币66.67亿元，同比上升16.5%，主要来自单抗药物销售及研究与授权服务的持续增长。期内毛利为49.85亿元，增幅达19.1%，带动年内利润达到8.27亿元，较上一年度的8.20亿元小幅增长0.8%。报告期内，研发支出达15.15亿元，同比攀升46.4%，公司持续加码肿瘤免疫治疗等创新药的临床试验与全球商用化推进。财务结构上，截至报告期末，公司资产净值为396.05亿元，同比增长31.4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖2025年营收增长16.5%至66.67亿元，聚焦创新研发与全球化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892567","title":"港股异动 | 复宏汉霖(02696)午后涨近5% 复宏汉霖TCE平台数据首秀2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892567","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629892567?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:42","pubTimestamp":1777009339,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖午后涨近5%，截至发稿，涨3.91%，报82.35港元，成交额6172.94万港元。消息面上，复宏汉霖近日在2026年美国癌症研究协会年会上以壁报形式首次公布了其在研新型CD3×CD28×STEAP1靶向三特异性T细胞衔接器HLX3902的临床前研究数据。西部证券此前发布研报称，预计2026-2028年公司营收为73.97/80.39/95.35亿元，同比增长11.0%/8.7%/18.6%。公司创新布局成效显著，临床数据读出、潜在BD预期等催化较多，叠加生物类似药出海增厚业绩，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","BK4588","BK4585","HK0000320223.HKD","HK0000165453.HKD","02696","HK0000320264.USD","BK1161","HK0000306685.HKD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209346","title":"复宏汉霖(02696)授出合共81万份购股权及81万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209346","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209346?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:43","pubTimestamp":1776429784,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，于2026年4月17日，董事会决议根据购股权计划及受限制股份单位计划分别向142名参与者授出合共81万份购股权及81万份受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000306685.HKD","HK0000320264.USD","HK0000165453.HKD","HK0000306701.USD","BK1161","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419200","title":"复宏汉霖(02696)：西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌(mCRC)治疗的1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419200","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419200?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:03","pubTimestamp":1776157393,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌治疗的1期临床试验申请获国家药品监督管理局批准。西妥昔单抗能与正常和肿瘤细胞中的EGFR特异性结合，竞争性抑制EGF等配体的结合。此外，西妥昔单抗还可通过抗体依赖的细胞毒性对部分肿瘤发挥抗肿瘤作用。根据IQVIA MIDASTM的资料，2025年度，西妥昔单抗注射液的全球销售额约为16.58亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌(mCRC)治疗的1期临床试验申请获国家药监局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000320223.HKD","HK0000320264.USD","HK0000165453.HKD","HK0000306701.USD","02696","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626416974","title":"港股复宏汉霖涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626416974","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626416974?lang=zh_cn&edition=full","pubTime":"2026-04-10 14:11","pubTimestamp":1775801495,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月10日，复宏汉霖(02696.HK)涨超4%，截至发稿涨4.44%，报83.55港元，成交额8776.22万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103700990064.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103700990064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","VXUS","BK1161","HK0000320223.HKD","HK0000320264.USD","BK4585","HK0000306685.HKD","HK0000306701.USD","02696","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626169444","title":"港股异动 | 复宏汉霖(02696)涨超4% 汉利康®新增两项适应症获批 7款创新管线将亮相AACR大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2626169444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626169444?lang=zh_cn&edition=full","pubTime":"2026-04-10 14:01","pubTimestamp":1775800905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨超4%，截至发稿，涨4.44%，报83.55港元，成交额8776.22万港元。消息面上，4月9日，复宏汉霖宣布，公司自主开发和生产的汉利康用于非霍奇金淋巴瘤下的两项新增适应症的补充申请获国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","VXUS","HK0000320223.HKD","HK0000320264.USD","HK0000165453.HKD","BK4588","HK0000306701.USD","02696","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626188257","title":"复宏汉霖(02696)：汉利康® (利妥昔单抗注射液)新增适应症的补充申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626188257","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626188257?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:52","pubTimestamp":1775728360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，本公司自主研发的汉利康® (利妥昔单抗注射液)(“汉利康®”)新增联合维泊妥珠单抗、环磷酰胺、多柔比星和泼尼松适用于治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者;及联合苯达莫司汀和维泊妥珠单抗适用于不适合接受造血干细胞移植的复发或难治性弥漫大B细胞淋巴瘤(DLBCL)成人患者两项适应症(“本次新增适应症”)的补充申请获国家药品监督管理局(“NMPA”)批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：汉利康® (利妥昔单抗注射液)新增适应症的补充申请获国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","HK0000165453.HKD","BK1161","HK0000306685.HKD","HK0000320223.HKD","02696","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154101955","title":"复宏汉霖汉利康（利妥昔单抗注射液）适应症扩展补充申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1154101955","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154101955?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:52","pubTimestamp":1775728332,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其核心产品汉利康（利妥昔单抗注射液）的适应症扩展补充申请，已正式获得国家药品监督管理局（NMPA）的批准。此次获批标志着该药物在临床应用范围上的进一步拓宽，有望为更多患者提供治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","02696","HK0000320223.HKD","BK1161","HK0000306701.USD","HK0000165453.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138335897","title":"复宏汉霖更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1138335897","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138335897?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:26","pubTimestamp":1775643965,"startTime":"0","endTime":"0","summary":"复宏汉霖于2026年4月8日公布了截至2026年3月31日的股份变动月报。报告显示，公司本月无新增发行或回购活动，整体已发行股本维持不变。根据公告，截至3月末，公司注册股本总额为543,494,853元人民币，其中已上市H股346,074,397股，非上市股份197,420,456股，上述数值与上月底持平。公司确认继续符合香港联交所相关公众持股量要求。截至报告期末，7,009,500份受限制股份单位仍在有效期内。本次月报由公司董事Wenjie ZHANG签署并向香港联交所提交。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509771","title":"对话复宏汉霖CEO朱俊：海外收入占比3%只是开始，将在欧美市场挖掘新增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509771","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624509771?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:24","pubTimestamp":1775132686,"startTime":"0","endTime":"0","summary":"\"\"近日，复宏汉霖发布了2025年年报，公司实现营业收入66.67亿元，同比增长16.5%；实现归母净利润8.27亿元，同比增长0.80%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693676396.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693676396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696","BK1161","HK0000165453.HKD","HK0000306685.HKD","HK0000320223.HKD","HK0000306701.USD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624359620","title":"复宏汉霖(02696)：帕妥珠曲妥珠单抗注射液(皮下注射)生物类似药HLX319的1期临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624359620","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624359620?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:04","pubTimestamp":1775034245,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主研发的帕妥珠曲妥珠单抗注射液生物类似药HLX319的1期临床试验申请获国家药品监督管理局批准。HLX319是公司自主研发的帕妥珠曲妥珠单抗注射液生物类似药，由活性成分曲妥珠单抗、帕妥珠单抗和辅料玻璃酸酶组成，拟用于早期乳腺癌的辅助/新辅助治疗与转移性乳腺癌的治疗。根据IQVIA MIDASTM的资料，2025年度，帕妥珠曲妥珠单抗注射液于全球的销售额约为30.23亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK1161","HK0000165453.HKD","02696","HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624456542","title":"港股异动 | 复宏汉霖(02696)涨超6% 自研HLXTEHAase02的1期临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624456542","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624456542?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:21","pubTimestamp":1775013673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨超6%，截至发稿，涨5.38%，报73.5港元，成交额8899.7万港元。消息面上，3月31日，复宏汉霖发布公告，近日，公司自主研发的HLXTEHAase02的1期临床试验申请获国家药品监督管理局批准。HLXTE-HAase02拟用于皮下给药产品的开发，帮助这些药物实现更有效的皮下递送。非临床研究显示，HLXTE-HAase02展现出与已上市重组人透明质酸产品相当的酶活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","HK0000306701.USD","VXUS","BK1161","02696","HK0000320223.HKD","HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184585813","title":"复宏汉霖HLXTE-HAASE02一期临床试验IND申请获中国药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1184585813","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184585813?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:02","pubTimestamp":1774951330,"startTime":"0","endTime":"0","summary":"复宏汉霖（HENLIUS）宣布，其创新药HLXTE-HAASE02的一期临床试验新药研究申请（IND）已获得中国国家药品监督管理局（NMPA）的正式批准。此次获批标志着该药物正式进入临床开发阶段，为公司肿瘤治疗领域的产品管线增添了新的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000306685.HKD","02696","HK0000320223.HKD","BK1161","HK0000165453.HKD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623003803","title":"复宏汉霖(02696)自主研发的HLXTEHAase02的1期临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2623003803","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623003803?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:00","pubTimestamp":1774951218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，公司自主研发的HLXTEHAase02的1期临床试验申请获国家药品监督管理局批准。HLXTE-HAase02在生理条件下可局部且可逆地特异性解聚皮下组织透明质酸，增大皮下给药体积，增强药物在皮下组织内的分散度和渗透性，进而增加药物的生物利用度，提高患者皮下给药的依从性。HLXTE-HAase02拟用于皮下给药产品的开发，帮助这些药物实现更有效的皮下递送。非临床研究显示，HLXTE-HAase02展现出与已上市重组人透明质酸产品相当的酶活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)自主研发的HLXTEHAase02的1期临床试验申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","HK0000306685.HKD","BK1161","HK0000165453.HKD","HK0000306701.USD","02696","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0819},{"period":"1month","weight":0.094},{"period":"3month","weight":0.3183},{"period":"6month","weight":0.0909},{"period":"1year","weight":0.987},{"period":"ytd","weight":0.3357}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.123428},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}